NERV Investors Who Stayed The Course Reap Rewards...

Shares of Minerva Neurosciences Inc. (NERV) rocketed up over 270% on Thursday, touching a new high of $13.22, thanks to positive phase II trial results of its drug candidates MIN-101 and MIN-117.

from RTT - Biotech http://ift.tt/27UUXDS
via IFTTT